e-Therapeutics, a British software firm offering a computational biotechnology platform, has opened an office in Nanjing that will allow the company to collaborate with biopharmas in China. The company’s software models the interactions of a given compound, predicting the degree to which it will bind with the body’s proteins. It can be used in drug discovery programs to predict efficacy as well as unwanted interactions. In September 2008, e-Therapeutics announced a partnership with Nanjing KeyGen Biotech. Co. Limited. More details...

Stock Symbols: (AIM: ETX) (SHA: 600713)